Moderna walked a tightrope trying to convince shareholders it can both develop a new portfolio of drugs and keep costs down in the process.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.
The company announced positive results in an early-stage trial of the individualized cancer vaccine it developed with Merck.
The company’s stock ran higher after the company buoyed investors’ hopes that its technology will boost a lineup of new popular drugs.
Pfizer’s stock slumped its lowest level in more than 10 years. The world’s moved on from the pandemic, and nobody loves you when you’re down.
Moderna posted a quarterly loss of $3.63 billion, half of which was accounted for by unused Covid-19 shots past their expiration date.
The weight loss drug market could be worth $100 billion in the next few years. Naturally, other companies want in.
No matter how you cast your ballot in the presidential election last month, recent history suggests your vote counts for IPOs.
The offer would put an 83% premium on Soho’s Wednesday closing price and comes a year after it had to close off admissions in three cities.
One ring to rule them all… at least, Oura hopes so. On Thursday, it announced a new $200 million funding round.